Moxeza

Moxeza is a brand name of moxifloxacin ophthalmic, approved by the FDA in the following formulation(s):

MOXEZA (moxifloxacin hydrochloride - solution/drops; ophthalmic)

• 
  Manufacturer: ALCON PHARMS LTD
  
  Approval date: November 19, 2010
  
  Strength(s): EQ 0.5% BASE ^[RLD]

Has a generic version of Moxeza been approved?

No. There is currently no therapeutically equivalent version of Moxeza available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Moxeza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  7-(1-pyrrolidinyl)-3-quinolone- and -naphthyridonecarboxylic acid derivatives as antibacterial agents and feed additives
  Patent 4,990,517
  Issued: February 5, 1991
  Inventor(s): Petersen; Uwe & Schenke; Thomas & Krebs; Andreas & Grohe; Klaus & Schriewer; Michael & Haller; Ingo & Metzger; Karl G. & Endermann; Rainer & Zeiler; Hans-Joachim
  Assignee(s): Bayer Aktiengesellschaft
  7-(1-Pyrrolidinyl)-3-quinolone- and -naphthyridonecarboxylic acid derivatives as antibacterial agents and feed additives, of the formula ##STR1## in which X.sup.1 is halogen, X.sup.2 is hydrogen, halogen, amino or other radical, R.sup.1 is alkyl, cycloalkyl, optionally substituted phenyl or other radical, R.sup.2 is hydrogen, alkyl or a dioxolylmethyl radical, R.sup.3 is ##STR2## A is N, CH, C-halogen, or the like, or forms a bridge with R.sup.1, and addition products thereof.
  
  Patent expiration dates:
  
  
  • December 8, 2011
    
    ✓ 
    Patent use: METHOD OF COMBATING BACTERIA IN A PATIENT
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • June 8, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives
  Patent 5,607,942
  Issued: March 4, 1997
  Inventor(s): Petersen; Uwe & Schenke; Thomas & Krebs; Andreas & Grohe; Klaus & Schriewer; Michael & Haller; Ingo & Metzger; Karl G. & Endermann; Rainer & Zeiler; Hans-Joachim
  Assignee(s): Bayer Aktiengesellschaft
  7-(1-Pyrrolidinyl)-3-quinolone- and -naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives, of the formula ##STR1## in which X.sup.1 is halogen, X.sup.2 is hydrogen, halogen, amino or other radical, R.sup.1 is alkyl, cycloalkyl, optionally substituted phenyl or other radical, R.sup.2 is hydrogen, alkyl or a dioxolylmethyl radical, R.sup.3 is ##STR2## and A is N, CH, C-halogen, or the like, or forms a bridge with R.sup.1, and addition products thereof.
  
  Patent expiration dates:
  
  
  • March 4, 2014
    
    ✓ 
    Patent use: METHOD OF COMBATING BACTERIA IN A PATIENT
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • September 4, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Ophthalmic antibiotic compositions containing moxifloxacin
  Patent 6,716,830
  Issued: April 6, 2004
  Inventor(s): Gerald; Cagle & Robert L.; Abshire & David W.; Stroman & John M.; Yanni
  Assignee(s): Alcon, Inc.
  Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.
  
  Patent expiration dates:
  
  
  • September 29, 2019
    
    ✓ 
    Drug product
  
  
  
  • March 29, 2020
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Method of treating ophthalmic infections with moxifloxacin compositions
  Patent 7,671,070
  Issued: March 2, 2010
  Inventor(s): Cagle; Gerald & Abshire; Robert L. & Stroman; David W. & Yanni; John M.
  Assignee(s): Alcon, Inc.
  Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.
  
  Patent expiration dates:
  
  
  • September 29, 2019
    
    ✓ 
    Patent use: METHOD OF COMBATING BACTERIA IN A PATIENT
    ✓ 
    Drug product
  
  
  
  • March 29, 2020
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • November 19, 2013 - NEW PRODUCT
  
  
  • May 19, 2014 - PEDIATRIC EXCLUSIVITY
  
  

See also...

• Moxeza Consumer Information (Drugs.com)
• Moxeza Drops Consumer Information (Wolters Kluwer)
• Moxeza Advanced Consumer Information (Micromedex)
• Moxifloxacin Drops Consumer Information (Wolters Kluwer)
• Moxifloxacin ophthalmic Consumer Information (Cerner Multum)
• Moxifloxacin Ophthalmic Advanced Consumer Information (Micromedex)
• Moxifloxacin Hydrochloride eent AHFS DI Monographs (ASHP)